Suven Pharmaceuticals Ltd
BSE : 543064|NSE : SUVENPHAR|ISIN : INE03QK01018
Suven Pharmaceuticals Ltd Company History
Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing
2020
2021
2022
2020
Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1.
2020
2021
CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology
transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG.
2021
2022
Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family.
Suven Pharmaceuticals approves acquisition of Casper Pharma.
2022
